Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Vortioxetine

Vortioxetine

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Vortioxetine

42 trials tracked of Vortioxetine: 32 in phase 3 or 4 and 1 with published results. The most-cited published study has 141 citations.

42Trials tracked
32Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 6 Phase 3 26 Phase 2 6 Phase 1 3 Other / NA 1
  1. Phase 3 THINC-it Vortioxetine - Sensitivity to Change Completed · 141 cited
  2. Phase 4 Vortioxetine for Posttraumatic Stress Disorder Completed
  3. Phase 4 Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder Completed
  4. Phase 4 Vortioxetine for Menopausal Depression Completed
  5. Phase 4 Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) Completed
  6. Phase 4 The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder Completed
Show 36 more trials
  1. Phase 4 Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers Completed
  2. Phase 3 Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed
  3. Phase 3 A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication Completed
  4. Phase 3 Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes Completed
  5. Phase 3 Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder Completed
  6. Phase 3 Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults Completed
  7. Phase 3 Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed
  8. Phase 3 Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults Completed
  9. Phase 3 Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed
  10. Phase 3 Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed
  11. Phase 3 Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder Completed
  12. Phase 3 Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed
  13. Phase 3 Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder Completed
  14. Phase 3 Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction Completed
  15. Phase 3 Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder Completed
  16. Phase 3 Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults Completed
  17. Phase 3 Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Completed
  18. Phase 3 Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder Completed
  19. Phase 3 Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients Completed
  20. Phase 3 Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries Completed
  21. Phase 3 Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder Completed
  22. Phase 3 Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder Completed
  23. Phase 3 A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder Completed
  24. Phase 3 Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study Completed
  25. Phase 3 An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder Completed
  26. Phase 3 Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder Completed
  27. Phase 2 Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder Completed
  28. Phase 2 Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults Completed
  29. Phase 2 Vortioxetine for Binge Eating Disorder Completed
  30. Phase 2 Vortioxetine for Post-COVID-19 Condition Completed
  31. Phase 2 Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults Completed
  32. Phase 2 Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder Completed
  33. Phase 1 Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment Completed
  34. Phase 1 A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets Completed
  35. Phase 1 Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults Completed
  36. N/A Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.